Bexxar tositumomab: Phase II data; BLA not acceptable for filing

In a Phase II trial of 76 previously untreated patients with advanced-stage low-grade NHL, Bexxar gave a complete remission in 76 percent of patients and tumor shrinkage in 97 percent of patients. In ...